Open AccessHumanization of fibroblast growth factor 1 single‐chain antibody and validation for its antitumorigenic efficacy in breast cancer and glioma cells
Author(s) -
He XiaoXiao,
Du Shuang,
Gao ShiQian,
Chen JingYing,
Cao RanJuan,
Xing ZhenKai,
Kazim Alia Rizvi Syeda,
Yu HuaLi,
Zheng QingChuan,
Zhu XiaoJuan
Publication year - 2018
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13547
Subject(s) - antibody , in vivo , in vitro , cancer research , antigen , glioma , biology , cancer , cancer cell , microbiology and biotechnology , immunology , chemistry , biochemistry , genetics
Single‐chain variable fragment (scFv) antibodies are the smallest immunoglobulins with high antigen‐binding affinity. We have previously reported that fibroblast growth factor 1 played pivotal roles in cancer development and generated a mouse scFv (mscFv1C9) could effectively prohibit cancer cell proliferation in vitro and in vivo. Here, we further humanized this scFv (hscFv1C9) using a structure‐guided complementarity determining region grafting strategy. The purified hscFv1C9 maintained similar antigen‐binding affinity and specificity as mscFv1C9, and it was capable of inhibiting growth of different tumours in vitro and in vivo. These data strongly suggested that hscFv1C9 has antitumour potentials.